WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, ...

Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growthCAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. “We are delighte ...

Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companiesARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and a ...

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host 1x1 investor meetings. Dat ...

Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive thera ...

Core Insights - 4D Molecular Therapeutics announced senior leadership changes to enhance focus on late-stage clinical trials and commercial readiness for its lead product candidate, 4D-150 [1][2][3] Leadership Changes - Dr. Julie Clark has been appointed as the new Chief Medical Officer, bringing over 20 years of experience in retina and global clinical development, including leadership roles in multiple BLA submissions and Phase 3 trials [3][5] - Liansheng Zhu, Ph.D., has joined as Senior Vice President of Biometrics and Data Quality, contributing nearly two decades of experience in late-stage clinical development and regulatory submissions [4][5] - Robert Kim, M.D., has stepped down from his role as Chief Medical Officer to pursue other opportunities [5] Clinical Development Focus - The 4FRONT-1 Phase 3 clinical trial for 4D-150 is on track to complete enrollment by Q1 2026, with current enrollment exceeding expectations [4][5] - 4D-150 is positioned as a backbone therapy for retinal vascular diseases, specifically targeting wet age-related macular degeneration and diabetic macular edema [8] Strategic Enhancements - The addition of senior retina leadership advisors aims to support the transition from late-stage development to commercial readiness [4] - The company emphasizes the importance of shared experience and complementary strengths among its leadership team to advance the 4D-150 program [3][5]

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be featured in 36 scientific oral and p ...

PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025. Post-Surgical Hypopa ...

Core Viewpoint - Theratechnologies Inc. has received recommendations from two independent proxy advisory firms, ISS and Glass Lewis, to vote "FOR" the special resolution for a plan of arrangement with CB Biotechnology, LLC, which involves a cash acquisition of the company's shares and contingent value rights [1][3][4]. Arrangement Details - The Purchaser will acquire all issued and outstanding common shares of Theratechnologies for a price of US$3.01 per Share in cash, plus one contingent value right per Share, which could provide additional cash payments of up to US$1.19 per CVR if certain milestones are achieved [2]. Recommendations from Advisory Firms - ISS recommends voting "FOR" the Arrangement due to the sizeable cash premium, additional upside from the CVRs, robust process, credible valuation, and non-approval risk [3]. - Glass Lewis supports the Arrangement, noting that the company undertook a reasonably extensive review process and that Future Pak presented the best offer after two broad market checks [4]. Board of Directors' Position - The Board of Directors unanimously recommends that shareholders vote "FOR" the Arrangement, considering it in the best interests of the company and fair to its shareholders [5]. Meeting Details - A special meeting for shareholders will be held on September 12, 2025, in a hybrid format, allowing both in-person and virtual attendance [6].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will ...